NCT06742216View on ClinicalTrials.gov

Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,232

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions
Acute Ischemic Stroke
Interventions
DRUG

Monosialoganglioside

Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

DRUG

Placebo

Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Trial Locations (1)

Unknown

Nanjing Gulou Medical College Affiliated Hospital, Nanjing

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06742216 - Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study | Biotech Hunter | Biotech Hunter